Daily Stock Opinions and Ratings

Opinions

Glenn Paradis, BA, CFA Labopharm Inc DDS-T PAST TOP PICK Apr 01, 2002

(Was a top pick on Dec 18 down 46%) Still likes. Got hit with the pull out of Aventis, but should be able to get new deals over the next 6 months. Don't buy until they do strike a deal.

Glenn Paradis, BA, CFA

Unknown

Unlock Rating

$5.800

Stock price when the opinion was issued

biotechnology pharmaceutical

It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

Get Signals Create your Watchlist

You might be interested:

DON'T BUY

Did an issue and it was a disaster. Hasn't even come close to where the issue was priced at. Behind schedule as compared to their competitors.

WATCH

Management is at its risk. If they start in Europe, the stock will improve. Therefore, be cautious.

DON'T BUY

Received approval in France for its drug tramadol. Has stubbed its toes many times with investors. Large outstanding stock holding (40 Million?) could come out and flood the market.

DON'T BUY

Drug companies in general scare value investors. Drugs they produce might injure or kill people. Also there's a history of companies suing each other because of infringement on property rights which can tie up a small company like this. Although they got French approval, FDA could be a whole different matter.

WATCH

Entering into a licensing/distribution agreement with Purdue Pharma in the US. Did a disatrous financing last year and the stock sold off. This deal was a rabbit pulled out of a hat. The stock will probably flatline for a bit after this deal. Best to see quarter after quarter how revenues kick in.

BUY

It is a small stock. Believes it will be a winner.

BUY

Has been doing fairly well recently because they had their European and Canadian approval for their painkiller. Once they get the US of the way, it should be back over the $7 mark.

SELL

Has been a major disappointment. Guided that approvals would be fairly easy to receive, which didn't happen. Trials have been okay, not all that inclusive, so there is a lot of uncertainty.

DON'T BUY

Has disappointed everyone for a long time. Didn't get approval on their product. Stock has been decimated. Thinks the worst is over, but it will be a long recovery. He was actually Short the stock for a while. If you own, Hold and see what they do, but don't be a buyer.

HOLD

Broke through the 200-day moving average at about $1.50. Looks like the momentum may start to peter out but there is some pretty good support around $1.40. If her broke that, you should Sell.

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

Glenn Paradis, BA, CFA Labopharm Inc DDS-T PAST TOP PICK Apr 01, 2002

You might be interested:

Labopharm Inc(DDS-T)

Labopharm Inc(DDS-T)

Labopharm Inc(DDS-T)

Labopharm Inc(DDS-T)

Labopharm Inc(DDS-T)

Labopharm Inc(DDS-T)

Labopharm Inc(DDS-T)

Labopharm Inc(DDS-T)

Labopharm Inc(DDS-T)

Labopharm Inc(DDS-T)

Latest Buy Signals

Today's Top Picks

Popular Articles

Latest Sell Signals

Most Recent Experts

Bruce Murray

The Panic-Proof Portfolio (Stockchase Research)

The Weekly Buzzing Stocks by Billy Kawasaki

Chris Blumas

Stockchase Insights